Route 92 Medical, a San Mateo, CA-based medical technology company, raised over $31M in Series F funding.
The round was led by existing venture capital investors U.S. Venture Partners, Norwest Venture Partners, InnovaHealth Partners, and The Vertical Group.
Led by CEO and Founder Tony Chou, Route 92 Medical is on a mission to improve outcomes for patients undergoing neurovascular intervention through engineering and product design. Route 92 Medical has developed a suite of reperfusion systems leveraging designs including the Tenzing® delivery catheter. These products are designed to work harmoniously as a system to improve the efficiency of endovascular thrombectomy procedures, enabling clinicians to quickly restore blood flow to a patient’s brain following acute ischemic stroke, the most common type of stroke affecting patients today.
The company intends to use the funds to accelerate the U.S. commercialization of the FreeClimb® 70 Reperfusion system featuring the FreeClimb 70 aspiration catheter and the Tenzing 7 delivery catheter. Funds will also be used to complete SUMMIT MAX, an FDA IDE-approved pivotal trial evaluating the HiPoint™ 88 and HiPoint 70 catheter systems, both featuring the Tenzing delivery catheter and support the company’s operational growth.
Route 92 Medical is completing the process validations of its first commercially available products from its new high-volume manufacturing plant near Salt Lake City, Utah. The new 40,000 square foot facility will provide over 12,000 square feet of production clean room, warehousing, and distribution function.